Cell line · CVCL_1483
Papers67
1 to 20 of 67
Download this page as JSON| Paper | Journal | Year | How we know | Retracted | Source |
|---|---|---|---|---|---|
| Circulating Tumour Cell GALNT13 Expression Is Associated with Prognosis and Treatment Response in Non-Small Cell Lung Cancer. | Int J Mol Sci | 2026 | Its Methods give the RRID and name the line | PubMed | |
| E3 ubiquitin ligase MAGI3‑mediated TAZ ubiquitination suppresses the non‑small cell lung cancer occurrence and development by targeting the Wnt pathway. | Int J Oncol | 2026 | Its Methods give the RRID and name the line | PubMed | |
| HES1 inhibition overcomes CDK4/6 inhibitor resistance by targeting cancer stemness in lung adenocarcinoma. | J Exp Clin Cancer Res | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Exosomal LINC00323 accelerates angiogenesis through activating the MAPK and JAK-STAT pathways by stabilizing CDC5L in NSCLC. | Cell Oncol (Dordr) | 2026 | Its Methods give the RRID and name the line | PubMed | |
| MPND Loss Epigenetically Activates TGFβ/SMAD3 Signaling to Drive Tumor Progression and Metastasis in Non-Small Cell Lung Cancer. | Cancer Res | 2026 | Its Methods give the RRID and name the line | PubMed | |
| A Zinc Finger Protein-Based Prognostic Model in Lung Adenocarcinoma Identifies FGD3 as a Marker Associated with Lorlatinib Resistance. | Cancers (Basel) | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Bioprinted Tumor Microenvironment Models Reveal Immune Evasion and Guide CAR-NK Therapeutic Strategies. | Adv Sci (Weinh) | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Early-stage multi-cancer detection through a plasma extracellular vesicle protein signature. | Cell Rep Med | 2026 | Its Methods give the RRID and name the line | PubMed | |
| CD146+ pericyte-like lung cancer brain metastatic stem cells promote tumor angiogenesis through dual regulatory effects on the VEGF/VEGFR axis. | Theranostics | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Nutrient Availability Dictates Cancer Metabolism-Based Therapeutic Responses to Nononcology Drugs. | Cancer Res | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Lung adenocarcinoma surfaceome remodeling with EGFR inhibitors uncovers placental alkaline phosphatase as a target for combination therapy. | Cell Rep Med | 2025 | Its Methods give the RRID and name the line | PubMed | |
| TIGIT Affects CAR NK-cell Effector Function in the Solid Tumor Microenvironment by Modulating Immune Synapse Strength. | Cancer Immunol Res | 2025 | Its Methods give the RRID and name the line | PubMed | |
| NRF2 regulates lipid droplet dynamics to prevent lipotoxicity. | iScience | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Utility of CK8/18 in identifying circulating tumor cells derived from lesions in patients with non-small cell lung cancer. | Transl Lung Cancer Res | 2025 | Its Methods give the RRID and name the line | PubMed | |
| A novel sensitizer reduces EGFR-TKI resistance by regulating the PI3K/Akt/mTOR pathway and autophagy. | Heliyon | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Efficacy of CBP/p300 Dual Inhibitors against Derepression of KREMEN2 in cBAF-Deficient Cancers. | Cancer Res Commun | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Improving PD-1 blockade plus chemotherapy for complete remission of lung cancer by nanoPDLIM2. | Elife | 2024 | Its Methods give the RRID and name the line | PubMed | |
| Defective N-glycosylation of IL6 induces metastasis and tyrosine kinase inhibitor resistance in lung cancer. | Nat Commun | 2024 | Its Methods give the RRID and name the line | PubMed | |
| N-Myristoytransferase Inhibition Causes Mitochondrial Iron Overload and Parthanatos in TIM17A-Dependent Aggressive Lung Carcinoma. | Cancer Res Commun | 2024 | Its Methods give the RRID and name the line | PubMed | |
| Type I interferon regulation by USP18 is a key vulnerability in cancer. | iScience | 2024 | Its Methods give the RRID and name the line | PubMed |
cell-lines-2026-11-14-0.1.0
Sources 4
- CellosaurusCC BY 4.0, with credit to Cellosaurus (SIB)
- PubMed Central's articlesTitles shown only for CC0, CC BY and public domain articles
- NLM's PMC Article DatasetsCourtesy of NLM, which does not endorse this database
- PubMedNLM's terms
Each source's terms
- CellosaurusCC BY 4.0. Cellosaurus's README: "we have chosen to apply the Creative Commons Attribution 4.0 International (CC BY 4.0) license to Cellosaurus (https://creativecommons.org/licenses/by/4.0/). This means that you are free to copy and redistribute Cellosaurus in any medium or format. You can remix, transform, and build upon Cellosaurus for any purpose, even commercially. You must give appropriate credit, provide a link to the license, and indicate if changes were made." Copyright (c) CALIPHO group, SIB Swiss Institute of Bioinformatics. Read on 14 Nov 2026 at https://ftp.expasy.org/databases/cellosaurus/README
- PubMed Central's articlesEach article's own license. Its words show only under CC0, CC BY or public domain
- NLM's PMC Article DatasetsNLM's PMC Article Datasets on AWS, https://registry.opendata.aws/ncbi-pmc. Its terms: users "acknowledge NLM as the source of the data in a clear and conspicuous manner", do not use the PubMed Central wordmark or the PMC logo, do not "indicate or imply that NLM/NIH/HHS has endorsed" a product, and "only distribute data that are licensed for redistribution". Each article keeps its own license: https://pmc.ncbi.nlm.nih.gov/about/copyright/
- PubMedNLM's terms
Cellosaurus, SIB Swiss Institute of Bioinformatics, https://www.cellosaurus.org, CC BY 4.0. Its problem notes are given in its own words.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/cell-lines/v1/CVCL_1483/papers